Close Menu

Bio-Rad

Of the 28 companies in the index, 18 firms saw their stock prices increase, while 10 firms' share prices decreased. 

The reimbursement rates for the most commonly performed SARS-CoV-2 serologic tests are $42.13 and $45.23, depending on the billing code used.

The listing enables assay developers and testing labs in the US to access the instrument for COVID-19 testing, the firm said.

Bio-Rad said it is withdrawing its previously issued annual revenue guidance given the uncertainties regarding the duration and impact of the COVID-19 pandemic.

The triplex assay can be used on the firm's QX200 or QXDx Droplet Digital PCR systems to process 93 patient samples per run.

The assay is designed to detect all human antibodies against SARS-CoV-2, including immunoglobulin M, immunoglobulin A, and immunoglobulin G.

Droplet digital PCR tests for SARS-CoV-2 can potentially detect the very low viral loads seen in asymptomatic and convalescent cases.

The companies are working together to secure US Food and Drug Administration Emergency Use Authorization for the digital droplet PCR test.

The firm saw low-single digit growth across its business segments in the quarter as well as in the full year. 

Pages